Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-cell stratified etanercept plus methotrexate for untreated early rheumatoid arthritis
ISRCTN17694963Phase 4Completed
- Sponsor
- University of Leeds
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, open-label trial of etanercept and methotrexate in rheumatoid arthritis (RA) (3 arms), sponsored by University of Leeds. Primary endpoint: Clinical remission at 24 weeks. Started Mar 2020; status: completed.
02
Drugs
etanerceptmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN17694963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17694963.